Navigation Links
Lorus Therapeutics Receives $600 Thousand From Escrow Account
Date:7/16/2008

evements that may be expressed or implied by such forward-looking statements, including, among others: our ability to obtain the capital required for research and operations, the inherent risks in early stage drug development including demonstrating efficacy, development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our Annual Information Form underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Lorus Therapeutics Inc.'s recent press releases are available through the Company's website at http://www.lorusthera.com. For Lorus' regulatory filings on SEDAR, please go to http://www.Sedar.com. For SEDAR filings prior to July 10, 2007 you wi
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
7. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
8. Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
11. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... 2015 , ... Capital Edge Consulting , a nationwide consulting firm that ... their ranking as one of the top 5000 companies listed on the 2015 ... nation. , “It is truly an honor to be recognized as one of America’s ...
(Date:8/27/2015)... Aug. 27, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... of regenerative medicine, today announced that executives from the ... month of September.  , Pedro ... & Renshaw,s 17th Annual Global Investment Conference on Wednesday, ... St. Regis Hotel in New York City ...
(Date:8/27/2015)... ... August 27, 2015 , ... Inc. Magazine released its annual ... Solutions as number 1,361 in growth for the three years through 2014. Being named ... fastest-growing privately held organizations in the country. , “We are thrilled to make ...
(Date:8/26/2015)... ... August 26, 2015 , ... MediVet Biologics, a ... US laboratory is to open in Manhattan, Kansas in early October, 2015. The ... growth of research and development through collaboration with researchers from Kansas State University’s ...
Breaking Biology Technology:Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3
... ) announces the following Webcast: , , , ... , , When:  July 20, 2010 @ ... Where:   http://www.investorcalendar.com/ClientPage.asp?ID=160518 , , , ... the web at the address above. , , , ...
... , QUEBEC CITY , July 14 ... TSX: AEZ) (the "Company"), a late-stage drug development ... announced that its partner, Keryx Biopharmaceuticals, Inc. ("Keryx") ... the U.S. Food and Drug Administration ("FDA") for ...
... July 14 Talecris Biotherapeutics Holdings Corp. (Nasdaq: ... and report form with respect to its proposed merger with ... with the Federal Trade Commission and the Antitrust Division of ... . Grifols has informed Talecris that their company filed its ...
Cached Biology Technology:Webcast Alert: Senesco Technologies (SNT) Announces the LHA Life Sciences & Med Tech Day 2010 Presentation 2Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma 2Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma 3Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma 4
(Date:8/18/2015)... Aug. 17, 2015 Research and Markets ... the "Global Biometric Authentication & Identification Market: ... & Forecast, 2015-2020" report to their offering. ... identification systems market is expected to grow at ... 2020 and generate over $25 billion (approximately) by ...
(Date:8/12/2015)... , August 12, 2015 As ... mobile payment innovation and advanced biometrics technology is accelerating ... way consumers rely on using their credit cards, the ... the future for payment services led by companies in ... ), :  Google, Inc. (NASDAQ: GOOG ), Apple ...
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, ... expected revenues in 2015 that relate to sales of FPC1155 for ... approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO of ... smartphone manufacturer in China and ... 155 for Z1 , ...
Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... German . , Max Planck scientists ... enzymes that catalyze chain elongation in an important secondary ... Phaedon cochleariae a single enzyme can trigger ... whether it is regulated by cobalt, manganese or magnesium ...
... [Brown University] A team of neuroengineers based at ... wireless brain sensor capable of relaying real-time broadband signals ... Several copies of the novel low-power device, described in ... performing well in animal models for more than year, ...
... analysis has found that a combination of methods that ... improve their physical health and lessen symptoms of depression. ... Nursing , the study indicates that clinicians should consider ... have poor nutrition and signs of depression. In ...
Cached Biology News:Metal ions regulate terpenoid metabolism in insects 2Metal ions regulate terpenoid metabolism in insects 3Brown unveils novel wireless brain sensor 2Brown unveils novel wireless brain sensor 3Brown unveils novel wireless brain sensor 4Helping dementia patients remember to eat well improves physical and mental health 2
... automates LC micro-fractionation, spotting and preparation ... system, LC eluent can be accurately ... in trace amounts. This allows for ... MALDI-TOF-MS measurements. When used in conjunction ...
... a unique new tool, OligoMix for low ... needs in genomics, proteomics, synthetic biology, drug ... MIXTURE of a large number of DESIGNED ... single microtube. OligoMix is made from an ...
... Capillary Electrophoresis Running Buffer was designed to ... demands of todays sequencing labs. As a ... to the gel-based sequencing community Sigma has ... to meet your buffer needs. Scientists at ...
... For knockdown of all human, ... siRNAs , Genomewide, predesigned siRNAs ... RNAi , Ready-to-use, convenient matching ... RT-PCR Cost-effective RNAi and ...
Biology Products: